Alnylam Pharma (ALNY) Tops Q2 EPS by $1.61
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of $0.56, $1.61 better than the analyst estimate of ($1.05). Revenue for the quarter came in at $659.8 million versus the consensus estimate of $449.18 million.
2024 Financial Guidance
Full year 2024 financial guidance has been updated as follows:
|
| Provided 2/15/2024 |
| Updated 8/1/2024 |
Combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO1 |
| $1,400 million - $1,500 million |
| $1,575 million - $1,650 million |
Net Product Revenue Growth vs. 2023 at reported FX rates1 |
| 13% to 21% |
| 27% to 33% |
Net Product Revenue Growth vs. 2023 at CER* |
| 13% to 21% |
| 28% to 34% |
Net revenues from collaborations and royalties  |
| $325 million - $425 million |
| $575 million - $650 million |
GAAP R&D and SG&A expenses |
| $1,900 million - $2,050 million |
| $2,000 million - $2,150 million |
Non-GAAP R&D and SG&A expenses2 |
| $1,675 million - $1,775 million |
| $1,775 million - $1,875 million |
|
|
|
|
|
1 Uses June 30, 2024 FX rates including: 1 EUR = 1.07 USD and 1 USD = 161 JPY | ||||
2 Primarily excludes $225 - $275 million of stock-based compensation expense from estimated GAAP R&D and SG&A expenses | ||||
*CER = Constant Exchange Rate, representing growth calculated as if the exchange rates had remained unchanged from those used in the twelve months ended December 31, 2023. CER is a non-GAAP measure. | ||||
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.